Lieu: Genopolys | Ville: Montpellier, France
Nicolas BLONDEAU est Directeur de Recherche au CNRS à l’Institut de Pharmacologie Moléculaire et Cellulaire à Nice.
Omega-3 alpha-linolenic acid for stroke management
Stroke is a worldwide main cause of mortality and morbidity. Preclinical studies have identified over 1000 molecules with brain-protective properties. More than 200 clinical trials have examined neuroprotection for ischemic stroke. To date most of them failed in clinical trials. Therefore testing alternative protective strategies to prevent stroke is of considerable importance.
Although there is a consensus that nutrition is important for health, its role is underestimated in stroke prevention. It is recognized that an increase consumption of salt, fatty foods and alcoholic beverages may promote pathologies like hypertension, obesity and alcoholism, all of which are well known risk factors of stroke. In contrast, it is more difficult to identify a risk factor arising from a deficiency in an essential nutrient in the diet. Western modern diets are deficient in omega-3 alpha- linolenic acid, which deficiency constitutes by itself a risk factor for cardiovascular diseases, including coronary heart disease and stroke. Furthermore, an imbalance in the consumption of omega-6 and omega-3 PUFAs progressively took place in the past 40 years leading to omega- 6/omega-3 ratios that are far above the WHO healthy recommendations.
In this context, nutritional products with health benefits represent a growing interest. Moreover, in today's world of processed food-like products and skyrocketing use and abuse of the term nutraceutical and functional food, nutritional products with health benefit represent a growing market escaping drug regulatory policies. It seems more important than ever to really understand how nutrition - with regards to PUFA- can have severe health consequences or provide health benefit.
Propulsé par iCagenda